TARA — Protara Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$3.86
-$0.04 (-1.03%)
Protara Therapeutics Inc (TARA) is a biotechnology company listed on NASDAQ. It is led by Jesse Shefferman, based in 345 Park Avenue South, New York, NY, United States, 10010, with about 46 employees. Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.
Net income was -$13.3M. TARA currently screens at market cap $228.8M.
Use this TARA page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the TARA quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the TARA SEC filings page. Lician reads the product cache first so this HTML stays unique to Protara Therapeutics Inc even when a live quote feed is slow.
About Protara Therapeutics Inc
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.
TARA Key Statistics
Market Cap
$228.75M
Volume
229,850
Previous Close
$3.85
Day Range
$3.71 – $3.89
P/B Ratio
1.26
EPS
-$2.17
Revenue
$0.00
Net Income
-$44.60M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
46
TARA Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$44.60M | -$40.42M | -$65.95M | -$47.25M |
| EPS (Diluted) | -$2.17 | -$3.57 | -$5.86 | -$4.21 |
Total Assets
$181.45M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$162.80M
Operating Cash Flow
-$35.81M
Free Cash Flow
$0.00
Protara Therapeutics Inc Company Information
- Co-founder, CEO, President & Director
- Jesse Shefferman
- Headquarters
- 345 Park Avenue South, New York, NY, United States, 10010
- Website
- www.protaratx.com
- Phone
- 646 844 0337
- IPO / Founded
- 2014-10-22
- Sector
- Healthcare
- Industry
- Biotechnology